IMRX
Immuneering Corp
$
3.220
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.285
Open
3.220
VWAP
3.21
Vol
190.61K
Mkt Cap
116.05M
Low
3.1008
Amount
610.92K
EV/EBITDA(TTM)
--
Total Shares
29.65M
EV
81.09M
EV/OCF(TTM)
--
P/S(TTM)
--
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Show More
4 Analyst Rating
237.89% Upside
Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 10.88 USD with a low forecast of 3.50 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
237.89% Upside
Current: 3.220
Low
3.50
Averages
10.88
High
21.00
237.89% Upside
Current: 3.220
Low
3.50
Averages
10.88
High
21.00
Mizuho
NULL
to
Outperform
maintain
$8 -> $10
2025-06-19
Reason
Mizuho
Price Target
$8 -> $10
2025-06-19
maintain
NULL
to
Outperform
Reason
Mizuho raised the firm's price target on Immuneering to $10 from $8 and keeps an Outperform rating on the shares. The company announced positive updated Phase 2a data for lead asset IMM-1-104 in first-line pancreatic cancer in combination with modified Gemcitabine, a standard-of-care treatment, the analyst tells investors in a research note. The firm came away "very impressed" by this first look at the overall survival and progression-free survival data.
Needham
Ami Fadia
Strong Buy
Reiterates
$12
2025-04-10
Reason
Needham
Ami Fadia
Price Target
$12
2025-04-10
Reiterates
Strong Buy
Reason
Chardan Capital
Geulah Livshits
Strong Buy
Maintains
$13
2025-03-24
Reason
Chardan Capital
Geulah Livshits
Price Target
$13
2025-03-24
Maintains
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$12
2025-03-21
Reason
Needham
Ami Fadia
Price Target
$12
2025-03-21
Reiterates
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$12
2025-02-06
Reason
Needham
Ami Fadia
Price Target
$12
2025-02-06
Reiterates
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$15
2025-01-13
Reason
Needham
Ami Fadia
Price Target
$15
2025-01-13
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Immuneering Corp (IMRX.O) is -1.92, compared to its 5-year average forward P/E of -3.89. For a more detailed relative valuation and DCF analysis to assess Immuneering Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.89
Current PE
-1.92
Overvalued PE
-0.17
Undervalued PE
-7.60
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.19
Current EV/EBITDA
-0.93
Overvalued EV/EBITDA
1.64
Undervalued EV/EBITDA
-6.01
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
317.31
Current PS
0.00
Overvalued PS
1151.61
Undervalued PS
-516.98
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+1.04%
-15.48M
Operating Profit
FY2025Q1
YoY :
+5.16%
-15.05M
Net Income after Tax
FY2025Q1
YoY :
-14.29%
-0.42
EPS - Diluted
FY2025Q1
YoY :
-9.27%
-14.09M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
12
334.1K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
12
334.1K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IMRX News & Events
Events Timeline
2025-08-13 (ET)
2025-08-13
16:34:27
New
Immuneering reports Q2 EPS (40c), consensus (40c)
2025-07-09 (ET)
2025-07-09
08:16:44
Immuneering granted atebimetinib patent by USPTO
2025-06-17 (ET)
2025-06-17
06:05:24
Immuneering's atebimetinibin shows positive survival data in pancreatic cancer
Sign Up For More Events
Sign Up For More Events
News
9.0
07-10NewsfilterCancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
5.0
06-23NASDAQ.COMMonday 6/23 Insider Buying Report: IMRX, DLTR
5.0
06-20NewsfilterWith Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Sign Up For More News
People Also Watch
OSTX
OS Therapies Inc
1.880
USD
+5.62%
SOTK
Sono-Tek Corp
3.230
USD
-0.92%
NEUE
NeueHealth Inc
6.665
USD
-1.26%
AIXI
Xiao-I Corp
1.570
USD
0.00%
MDBH
MDB Capital Holdings LLC
3.640
USD
-2.93%
INUV
Inuvo Inc
3.780
USD
-2.58%
MATH
Metalpha Technology Holding Ltd
2.740
USD
-2.84%
CRT
Cross Timbers Royalty Trust
8.680
USD
+0.93%
TORO
Toro Corp
2.810
USD
-3.77%
KOSS
Koss Corp
5.480
USD
+2.24%
FAQ
What is Immuneering Corp (IMRX) stock price today?
The current price of IMRX is 3.22 USD — it has decreased -0.92 % in the last trading day.
What is Immuneering Corp (IMRX)'s business?
What is the price predicton of IMRX Stock?
What is Immuneering Corp (IMRX)'s revenue for the last quarter?
What is Immuneering Corp (IMRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Immuneering Corp (IMRX)'s fundamentals?
How many employees does Immuneering Corp (IMRX). have?